Goldman Sachs Reiterates Buy on Incyte (INCY)

Goldman Sachs reiterated a Buy rating and $97.00 price target on Incyte (NASDAQ: INCY) following the company's investor event. INCY showcased its five product late-stage portfolio in development for 15 indications.

INCY continues to advance multiple clinical development programs for patients with myeloproliferative neoplasms (MPNs) that have not responded to, or are unable to tolerate Jakafi monotherapy.

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $72.49 yesterday.

You May Also Be Interested In

• Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Freedom Broker Upgrades Allstate (ALL) to Buy
• Stephens Downgrades Papa John\'s (PZZA) to Equal Weight